Seven charges usually sit outside the advertised price: a membership or platform fee, the dose-tier increase, lab work, shipping, injection supplies, follow-up or refill consultation fees, and the renewal rate once a promotional period ends. An eighth is what a prepaid multi-month plan forfeits when someone stops early.
The advertised figure describes week one
Nearly every quoted price in this market refers to the lowest starting strength during an introductory window. That is not dishonest on its own, since treatment does begin there. It is misleading as a planning number, because these regimens are designed to escalate. Trial protocols for both semaglutide and tirzepatide involve stepping up over months to reach target strengths, so nobody who continues stays at the entry dose.
The number worth comparing is what the strength a person would plausibly be on by month six costs, with every recurring charge added. Two programs that advertise nearly identical opening figures can diverge by several hundred dollars across a year once the dose ladder and the fee structure are applied.
Membership fees stacked on medication charges
Some services separate a platform or membership fee from the medication charge. The membership covers clinical access and program tools, the medication is billed separately, and only the smaller of the two appears in advertising. Others fold everything into one figure. Neither model is inherently better value, but comparing a bundled figure against an unbundled one produces nonsense.
The clarifying question is short: what is the total amount billed in a typical month, across all line items, at a stated strength. Ask it that way and the structure stops mattering.
Dose tiers are the largest single variable
Programs handle escalation in one of two ways. Flat-rate pricing holds the same monthly charge at any strength. Tiered pricing raises the charge as the dose rises, sometimes substantially between the second and fourth steps. A tiered program can open below a flat-rate competitor and finish well above it.
Published price schedules make this checkable in advance, and disclosure varies across the field. Cash-pay compounded programs including Henry Meds, Mochi, Eden, and FormBlends post per-strength figures, while several larger platforms show an opening rate and reveal the ladder after intake. Manufacturer channels such as LillyDirect and NovoCare Pharmacy publish per-fill vial pricing for the approved brand products, which changes periodically, so the figure shown at the moment of ordering is the only one worth planning around.
| Charge | Where it hides | Question that surfaces it |
|---|---|---|
| Membership or platform fee | Billed separately from medication | What is the total billed per month, all items included? |
| Dose-tier increase | Price schedule shown after intake | What does the highest available strength cost? |
| Lab work | Required but not included | Are baseline or follow-up labs required, and who pays? |
| Shipping | Free at one cadence, charged at another | Is shipping included on every order, including reships? |
| Injection supplies | Syringes, needles, alcohol wipes sold separately | Are supplies included with each shipment? |
| Follow-up or refill fee | Charged per visit or per renewal | Is any charge attached to a dose change or refill? |
| Renewal rate | Introductory pricing expires quietly | What is the price in month four at the same strength? |
Labs, supplies, and shipping
Baseline lab work is a real clinical item, not an upsell in itself. Programs handle it three ways: included in the fee, ordered and billed to the patient, or not requested at all. The third option is not automatically cheaper, since testing that is clinically warranted simply moves onto a different bill later.
Supplies sound trivial and are not, because they recur weekly. A program that ships medication without syringes leaves the patient sourcing them, and the syringe type has to match how the dose is expressed. Shipping deserves one specific question about reships, since a temperature failure in transit is common enough that who pays for the replacement is a live issue rather than a hypothetical.
The renewal cliff and prepaid plans
Introductory pricing in this market is frequently tied to a prepaid commitment of three, six, or twelve months. Prepaying lowers the monthly figure and transfers risk to the customer. If the medication is not tolerated at week four, the question becomes what the refund terms are on the unused balance, and answers range from a full pro rata refund to nothing at all.
That risk is worth weighing against how long treatment realistically continues. Follow-up data on semaglutide showed substantial regain of lost weight after withdrawal, so this is not usually a short course. On the other hand, a prepaid year with a provider whose dose ceiling turns out to be too low is money spent on a plan that has to be abandoned partway through.
Comparing that prepaid risk across services is easier when each one publishes its terms up front. Ro and Hims and Hers usually state membership and cancellation rules while revealing higher-tier pricing later, manufacturer channels like LillyDirect and NovoCare list per-vial figures for the approved brands, and a provider such as HealthRX shows the GLP-1 medications it offers with pricing attached. Lining those disclosures up beside one another is the only way the true twelve-month cost, and the true cost of leaving, becomes visible.
Frequently asked questions
How much of the total can be pinned down before signing up?
Most of it. Membership, dose-tier pricing, shipping, supplies, and renewal rates are all business terms a service can state on request. Only lab costs depend on outside billing. A provider unwilling to give a full schedule at every strength is asking for a commitment on incomplete information.
Is a prepaid multi-month plan a mistake?
Not if the medication is already tolerated and the dose is settled. It is a poor bet at the very start, when the chance of stopping for side effects is highest. Waiting a month or two before prepaying costs a little more per month and removes most of the downside.
Do these programs ever bill insurance?
Cash-pay services generally do not, and compounded preparations are not covered by plans in any case. Where a plan covers an approved anti-obesity medication, the copay route can be cheaper than any cash program, though it typically requires prior authorization. Medicare drug coverage has historically excluded agents used for weight loss alone.
Does a higher price indicate a better program?
Not reliably. Price mostly tracks the medication pathway, since approved brand products cost more than compounded preparations, and how much service is bundled. Within the same pathway, price differences reflect margin and marketing spend more than clinical depth.
What is the fastest way to compare two quotes fairly?
Price twelve months at each, using the strength expected by month six, adding every recurring line item, and applying the post-promotional rate from the month it starts. That single figure is comparable across services. The advertised monthly number is not comparable to anything.
